Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?

被引:5
|
作者
Larouche, Genevieve [1 ,2 ,3 ]
Chiquette, Jocelyne [2 ,3 ,4 ,5 ]
Pelletier, Sylvie [2 ,3 ]
Simard, Jacques [2 ,3 ,5 ,6 ]
Dorval, Michel [1 ,2 ,3 ,4 ]
机构
[1] Univ Laval, Fac Pharm, Quebec City, PQ, Canada
[2] Univ Laval, Ctr Rech, CHU Quebec, Quebec City, PQ, Canada
[3] Univ Laval, Ctr Rech Canc, Quebec City, PQ, Canada
[4] Univ Laval, CHU Quebec, Ctr Malad Sein Deschenes Fabia, Quebec City, PQ, Canada
[5] Univ Laval, Fac Med, Quebec City, PQ, Canada
[6] Univ Laval, Chaire Rech Canada Oncogenet, Quebec City, PQ, Canada
基金
加拿大健康研究院;
关键词
Genes BRCA 1; Genes BRCA 2; Mammography; Breast cancer genetic testing; Breast cancer screening;
D O I
10.1007/s10689-016-9920-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Little is known about the change in mammograms use by women after BRCA1/2 genetic testing. We compared the rate of bilateral mammograms after and prior to BRCA1/2 testing, according to test result. Information from the Quebec Health Insurance Board database was used to identify all registered mammograms delivered between May 1, 1998 and March 31, 2012 to a cohort of 396 unaffected French Canadian women tested for BRCA1/2 mutations. Mammograms incidence density ratios were calculated using the Cox proportional hazards model for repeated events. BRCA1/2 mutation carriers and women with an inconclusive result had more mammograms after, than prior to, genetic testing. Non-carriers did not receive more mammograms. The observed increase in mammography screening in BRCA1/2 carriers is consistent with the high risk of developing breast cancer in this group. The estimation of the cancer risk associated with an inconclusive result is based on familial cancer history, and women who received this result appear to have received follow-up as if at high risk. The fact that non-carriers did not change their use of mammograms after genetic testing may possibly reflect a 'defensive medicine' approach by some physicians or the women's preference.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 50 条
  • [31] CONTRALATERAL MASTECTOMY AND BRCA1 AND BRCA2 Threshold for genetic testing in women with breast cancer needs to be determined
    Basu, Narendra Nath
    Barr, Lester
    Evans, D. Gareth
    Ross, Gary L.
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
  • [32] BRCA1/2 testing in hereditary breast and ovarian cancer families III:: Risk perception and screening
    McInerney-Leo, Aideen
    Hadley, Donald
    Kase, Ronald G.
    Giambarresi, Therese R.
    Struewing, Jeffery P.
    Biesecker, Barbara Bowles
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2006, 140A (20) : 2198 - 2206
  • [33] TESTING FOR BRCA1 IN HEREDITARY BREAST-CANCER
    VANCE, GH
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (11): : 845 - 846
  • [34] Compliance With Tamoxifen in Women With Breast Cancer and a BRCA1 or BRCA2 Mutation
    Narod, Steven A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (33) : E698 - E699
  • [35] Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations
    Lu Yao
    Jie Sun
    Juan Zhang
    Yingjian He
    Tao Ouyang
    Jinfeng Li
    Tianfeng Wang
    Zhaoqing Fan
    Tie Fan
    Benyao Lin
    Yuntao Xie
    Breast Cancer Research and Treatment, 2016, 156 : 441 - 445
  • [36] Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations
    Metcalfe, Kelly A.
    WOMENS HEALTH, 2009, 5 (01) : 63 - 68
  • [37] Recurrent BRCA1 and BRCA2 Mutations in Mexican Women with Breast Cancer
    Torres-Mejia, Gabriela
    Royer, Robert
    Llacuachaqui, Marcia
    Akbari, Mohammad R.
    Giuliano, Anna R.
    Martinez-Matsushita, Louis
    Angeles-Llerenas, Angelica
    Ortega-Olvera, Carolina
    Ziv, Elad
    Lazcano-Ponce, Eduardo
    Phelan, Catherine M.
    Narod, Steven A.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (03) : 498 - 505
  • [38] Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation
    Kotsopoulos, Joanne
    Gronwald, Jacek
    Huzarski, Tomasz
    Aeilts, Amber
    Armel, Susan Randall
    Karlan, Beth
    Singer, Christian
    Eisen, Andrea
    Tung, Nadine
    Olopade, Olufunmilayo
    Bordeleau, Louise
    Eng, Charis
    Foulkes, William
    Neuhausen, Susan
    Cullinane, Carey
    Pal, Tuya
    Fruscio, Robert
    Lubinski, Jan
    Metcalfe, Kelly
    Sun, Ping
    Narod, Steven
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (02) : 257 - 264
  • [39] Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation
    Joanne Kotsopoulos
    Jacek Gronwald
    Tomasz Huzarski
    Amber Aeilts
    Susan Randall Armel
    Beth Karlan
    Christian F. Singer
    Andrea Eisen
    Nadine Tung
    Olufunmilayo Olopade
    Louise Bordeleau
    Charis Eng
    William D. Foulkes
    Susan L. Neuhausen
    Carey A. Cullinane
    Tuya Pal
    Robert Fruscio
    Jan Lubinski
    Kelly Metcalfe
    Ping Sun
    Steven A. Narod
    Breast Cancer Research and Treatment, 2023, 201 : 257 - 264
  • [40] BRCA1/BRCA2 mutations and breast cancer in Ashkenazi Jewish women
    Gilbert, F
    Dabney, MK
    Diemer, K
    Ludwig, S
    Rosenthal, G
    Osborne, MP
    CANCER: GENETICS AND THE ENVIRONMENT, 1997, 833 : 198 - 203